There are 2789 resources available
813P - Efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): A multicenter, phase II clinical trial
Presenter: Kosei Hasegawa
Session: ePoster Display
814P - Prevalence of HER2 overexpression and amplification in uterine cervical cancer: A systematic review and a meta-analysis
Presenter: Boris Itkin
Session: ePoster Display
815TiP - ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI)
Presenter: Susana Banerjee
Session: ePoster Display
817TiP - GYNET study - Safety and efficacy of anti-netrin 1 (NP137) in combination with chemotherapy and/or pembrolizumab in patients (pts) with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: An adaptive multi-arms randomized phase I/II trial
Presenter: Isabelle Ray-Coquard
Session: ePoster Display
820TiP - ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)
Presenter: Mansoor Raza Mirza
Session: ePoster Display
821TiP - GREAT: A multicentric cohort of advanced ovarian cancer (AOC) treated in real life with prospective collection of clinical data, tumor sample, and biomarkers (tBRCA, HRD) including genomic putative theranostic markers: A GINECO study
Presenter: Thibault De La Motte Rouge
Session: ePoster Display
822TiP - BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy
Presenter: Isabelle Ray-Coquard
Session: ePoster Display
Resources:
Abstract